Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2006;47:811-815
Published online before print March 6, 2006, doi: 10.1161/01.HYP.0000209020.69734.73
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
47/5/811    most recent
01.HYP.0000209020.69734.73v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Reudelhuber, T. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reudelhuber, T. L.
Related Collections
Right arrow ACE/Angiotension receptors

(Hypertension. 2006;47:811.)
© 2006 American Heart Association, Inc.


Hypertension Highlights

A Place in Our Hearts for the Lowly Angiotensin 1-7 Peptide?

Timothy L. Reudelhuber

From the Laboratory of Molecular Biochemistry of Hypertension, Clinical Research Institute of Montreal, Montreal, Quebec, Canada.

Correspondence to Timothy L. Reudelhuber, 110 Pine Ave W, Montreal, Quebec, Canada H2W 1R7. E-mail reudelt@ircm.qc.ca


An extract of the first 250 words of the full text is provided, because this article has no abstract.
 


*    Introduction
 
It is absolutely astounding that over a hundred years after the discovery of renin, important new discoveries continue to be made concerning the importance of the renin–angiotensin system (RAS) in biology and disease. In addition to its accepted role as a modulator of blood pressure and fluid volume, it is now clear that the RAS contributes to renal development (reviewed in Reference 1), and mounting evidence suggests that it modulates memory and cardiac and respiratory function. Most of the recent discoveries revolve around peptide products of the RAS that were previously thought to be simply breakdown products but that are increasingly taking center stage in physiology and pathophysiology.

The RAS is classically described as a circulating enzymatic pathway of which the sole product of importance is the vasoactive peptide angiotensin II (Ang II; Figure 1). Inhibition of the RAS is now the major pharmacological target in North America for prevention of hypertension and a host of other cardiovascular complications. Although Ang II plays a key role in the biology of the RAS, it is certainly not the only biologically active peptide produced by this system, particularly within tissues (Figure 1). For example, Ang II can be converted to smaller peptide products with biological activity by the action of aminopeptidase A, which removes a single amino acid from the amino terminus of Ang II to produce angiotensin III (Ang III or Ang 2-8). Additional action of aminopeptidases can generate the hexapeptide angiotensin IV (Ang IV or Ang 3-8). . . . [Full Text of this Article]




This article has been cited by other articles:


Home page
Reproductive SciencesHome page
J. Vaz-Silva, M.M. Carneiro, M.C. Ferreira, S.V.B. Pinheiro, D.A. Silva, A.L. Silva Filho, C.A. Witz, A.M. Reis, R.A. Santos, and F.M. Reis
The Vasoactive Peptide Angiotensin-(1--7), Its Receptor Mas and the Angiotensin-converting Enzyme Type 2 are Expressed in the Human Endometrium
Reproductive Sciences, March 1, 2009; 16(3): 247 - 256.
[Abstract] [PDF]


Home page
Circ. Res.Home page
J. A. Stewart Jr, E. Lazartigues, and P. A. Lucchesi
The Angiotensin Converting Enzyme 2/Ang-(1-7) Axis in the Heart: A Role for Mas Communication?
Circ. Res., November 21, 2008; 103(11): 1197 - 1199.
[Full Text] [PDF]


Home page
Exp PhysiolHome page
A. Zulli, S. Rai, B. F. Buxton, L. M. Burrell, and D. L. Hare
Co-localization of angiotensin-converting enzyme 2-, octomer-4- and CD34-positive cells in rabbit atherosclerotic plaques
Exp Physiol, May 1, 2008; 93(5): 564 - 569.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
S. Keidar, M. Kaplan, and A. Gamliel-Lazarovich
ACE2 of the heart: From angiotensin I to angiotensin (1-7)
Cardiovasc Res, February 1, 2007; 73(3): 463 - 469.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
G.Y. Oudit, A.M. Herzenberg, Z. Kassiri, D. Wong, H. Reich, R. Khokha, M.A. Crackower, P.H. Backx, J.M. Penninger, J.W. Scholey, et al.
Angiotensin-Converting Enzyme-2 (ACE2)--A New Player in the Genesis of Glomerular Injury?: Loss of Angiotensin-Converting Enzyme-2 Leads to the Late Development of Angiotensin II-Dependent Glomerulosclerosis. Am J Pathol 168: 1808-1820, 2006
J. Am. Soc. Nephrol., October 1, 2006; 17(10): 2637 - 2643.
[Full Text] [PDF]